Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Low-dose blinatumomab — a T-cell engager typically used in blood cancers — showed promising results in patients with multidrug-resistant rheumatoid arthritis (RA). In a small German case series, the drug triggered short-term remission and depleted disease-driving B cells in the joints. Perhaps most intriguingly, some patients who had previously failed standard therapies began responding to them again after treatment.
Blinatumomab, a T-cell engager best known for treating blood cancers, is showing early promise in a very different arena: multidrug-resistant rheumatoid arthritis (RA). A small German case series of 15 patients — all of whom had failed methotrexate and at least three other targeted or biologic therapies — found that low-dose blinatumomab induced short-term clinical remission, reduced joint inflammation, and depleted B cells from the synovium (the tissue lining the joints).
One of the most striking findings? After initial flares post-treatment, 7 of 9 retreated patients responded to DMARDs they had previously failed — suggesting the drug may help "reset" the immune system, even if it doesn't cure the disease outright.
By the Numbers:
Why it matters: For patients who've exhausted standard RA options, this approach could represent a meaningful bridge — not just offering temporary relief, but potentially restoring sensitivity to existing therapies. Researchers caution the study is small and exploratory, but call low-dose protocols a "pragmatic and immediately valuable clinical advancement."
